A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong

Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience

“…Nonetheless, the result here underscores the pivotal importance of dose escalation in the local control of NPC and demonstrates a definite dose-response relationship beyond 66 Gy. Other evidence supporting dose escalation comes from the positive results of several nonrandomized studies using brachytherapy and parapharyngeal boost in T1 to T2b disease (1)(2)(3)(4).…”

“…Despite the recognized radiocurability and evidence of a dose-response relationship for nasopharyngeal carcinoma (NPC) (1)(2)(3)(4), radiotherapy (RT) treatment planning remains a great challenge in view of the close proximity of the tumor to the surrounding neural organs. Any attempt to perform dose escalation will be limited by the low radiation tolerance of the adjacent organs at risk (OAR)-namely, the brainstem, spinal cord, temporal lobes, and optic pathway.…”

Staging of nasopharyngeal carcinoma: From Ho's to the new UICC system

“…This was not specified as a T-stage criterion in the previous UICC/AJCC systems, and none of the western series reported independent significance attributed to this factor (Sanguineti et al, 1997). On the other hand, poor prognosis has been suggested by some Asian studies (Chua et al, 1997;Min et al, 1994;Sham and Choy, 1991;Teo et al, 1989Teo et al, , 1992Teo et al, , 1996.…”

Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type

“…[17][18][19] The occurrence of distant metastasis is higher in patients with N3 disease, reaching 65% to 83% at 5 years. [20][21][22][23] Neoadjuvant chemotherapy has been tested in advanced bulky locoregional disease to improve both locoregional and distant failure. Several studies have shown that UCNT is highly sensitive to preirradiation chemotherapy.…”